肿瘤细胞治疗研究
英文原题：B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
套细胞淋巴瘤（MCL）是B细胞非霍奇金淋巴瘤（NHL）的一种异质性亚型。
套细胞淋巴瘤（MCL）是B细胞非霍奇金淋巴瘤（NHL）的一种异质性亚型。近年来，随着共价BTK抑制剂的应用、用于评估可测量残留病（MRD）的敏感检测方法以及预先设定的维持或持续治疗，新诊断MCL的治疗格局已发生变化。基于共价BTK抑制剂的方案也适用于既往未经治疗的伴TP53突变的经典型MCL患者。Pirtobrutinib（一种高选择性非共价BTK抑制剂）和CAR T细胞疗法（brexucabtagene autoleucel或lisocabtagene maraleucel）已成为既往接受共价BTK抑制剂治疗后难治或进展性疾病的有效治疗选择。本部分选自NCCN B细胞淋巴瘤指南，重点介绍MCL的诊断和治疗推荐。
Mantle cell lymphoma (MCL) is a heterogenous subtype of B-cell non-Hodgkin lymphoma (NHL). The treatment landscape of newly diagnosed MCL has evolved in recent years with the incorporation of covalent BTK inhibitors, sensitive assays for the assessment of measurable residual disease (MRD), and predefined maintenance or continuous therapy. Covalent BTK inhibitor-based regimens are also appropriate options for patients with previously untreated classic MCL with TP53 mutations. Pirtobrutinib (a highly selective noncovalent BTK inhibitor) and CAR T-cell therapy (brexucabtagene autoleucel or lisocabtagene maraleucel) have emerged as effective treatment options for refractory or progressive disease after prior treatment with covalent BTK inhibitors. This selection from NCCN Guidelines for B-Cell Lymphomas focuses on the recommendations for the diagnosis and treatment of MCL.
MEMBER ACCOUNT
登录成功会直接打开下一页。
